Interim estimates of 2019-20 seasonal influenza vaccine effectiveness - United States, February 2020

Morbidity and Mortality Weekly Report

Volumn 69, Issue 7, 2020, Pages 177-182

  Dawood, Fatimah S ^a   Chung, Jessie R ^a   Kim, Sara S ^a   Zimmerman, Richard K ^b   Nowalk, Mary Patricia ^b   Jackson, Michael L ^c   Jackson, Lisa A ^c   Monto, Arnold S ^d   Martin, Emily T ^d   Belongia, Edward A ^e   McLean, Huong Q ^e   Gaglani, Manjusha ^f   Dunnigan, Kayan ^f   Foust, Angie ^a   Sessions, Wendy ^a   DaSilva, Juliana ^a   Le, Shoshona ^a   Stark, Thomas ^a   Kondor, Rebecca J ^a   Barnes, John R ^a   Wentworth, David E ^a   Brammer, Lynnette ^a   Fry, Alicia M ^a   Patel, Manish M ^a   Flannery, Brendan ^a   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MARSHFIELD CLINIC   (United States)

^f TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOLOGY; INFANT; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; SEASON; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SEASONS; UNITED STATES; YOUNG ADULT;

EID: 85080850078     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6907a1     Document Type: Review

References (10)

1. Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2019-20 influenza season. MMWR Recomm Rep 2019;68(No. RR-3). https://doi.org/10.15585/mmwr.rr6803a1
2. Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 2017;377:534-43. https://doi.org/10.1056/NEJMoa1700153
3. Owusu D, Hand J, Tenforde MW, et al. Early season pediatric influenza B/Victoria virus infections associated with a recently emerged virus subclade-Louisiana, 2019. MMWR Morb Mortal Wkly Rep 2020;69:40-3. https://doi.org/10.15585/mmwr.mm6902e1
4. Doyle JD, Campbell AP. Pediatric influenza and illness severity: what is known and what questions remain? Curr Opin Pediatr 2019;31:119-26. https://doi.org/10.1097/MOP.0000000000000721
5. Tran D, Vaudry W, Moore D, et al.; members of the Canadian Immunization Monitoring Program Active. Hospitalization for influenza A versus B. Pediatrics 2016;138:e20154643. https://doi.org/10.1542/peds.2015-4643
6. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016;16:942-51. https://doi.org/10.1016/S1473-3099(16)00129-8
7. Xu X, Blanton L, Elal AI, et al. Update: influenza activity in the United States during the 2018-19 season and composition of the 2019-20 influenza vaccine. MMWR Morb Mortal Wkly Rep 2019;68:548-51. https://doi.org/10.15585/mmwr.mm6824a3
8. Doyle JD, Chung JR, Kim SS, et al. Interim estimates of 2018-19 seasonal influenza vaccine effectiveness-United States, February 2019. MMWR Morb Mortal Wkly Rep 2019;68:135-9. https://doi.org/10.15585/mmwr.mm6806a2
9. Chung JR, Rolfes MA, Flannery B, et al. Effects of influenza vaccination in the United States during the 2018-2019 influenza season. Clin Infect Dis 2020;69:ciz1244. https://doi.org/10.1093/cid/ciz1244
10. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013;18:20585. https://doi.org/10.2807/15607917.ES2013.18.37.20585